Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
Source abstract
Abstract
The emerging CRISPR/Cas9 system represents a promising platform for genome editing. However, its low transfection efficiency is a major problem hampering the application of the gene-editing potential of CRISPR/Cas9. Herein, by screening a pool of more than 56 kinds of agents, we constructed a novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core–shell structure (PLNP/DNA) that mediated up to 47.4% successful transfection of Cas9/sgPLK-1 plasmids in A375 cells in vitro. An intratumor injection of Cas9/sgPLK-1 plasmids into melanoma tumor-bearing mice resulted in significant downregulation of Polo-like kinase 1 (PLK-1) protein and suppression of the tumor growth (>67%) in vivo. This approach provides a versatile method that could be used for delivering the CRISPR/Cas9 system with high efficiency and safety both in vitro and in vivo. A material for delivering CRISPR–Cas9 to the nuclei of cells has been developed by researchers in China. CRISPR–Cas9 is a powerful gene editing system found in bacteria. Scientists have recently harnessed it to edit genes in mammalian cells and even human embryos, opening the door to a host of revolutionary medical treatments. But the plasmid encoding CRISPR–Cas9 is a large nucleic acid, which limits the efficiency with which it can enter target cells. Now, Xingyu Jiang from the National Center for Nanoscience and Technology, Beijing, and colleagues have demonstrated a versatile method for delivering CRISPR–Cas9 efficiently and safely. After screening more than 56 agents, they constructed polyethylene glycol phospholipid–modified cationic lipid nanoparticles to encapsulate CRISPR–Cas9, which allowed nanoparticles to be delivered to melanoma cells with an efficiency of 47%. Our work contributes to synthesize a vehicle based on lipid nanoparticles, which can effectively deliver Cas9/sgRNA-fused plasmid DNA in vitro and in vivo. This approach mediated successful transfection of Cas9/sgRNA plasmids in multiple cell lines in vitro. The vehicle carrying Cas9/sgRNA targeting PLK-1 resulted in significant down-regulation of PLK-1 protein and suppression of melanoma growth in vivo.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. Hsu, P. D., lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).10.1016/j.cell.2014.05.010 ↗
2. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014).10.1126/science.1246981 ↗
3. Chang, N., Sun, C., Gao, L., Zhu, D., Xu, X., Zhu, X., Xiong, J. W. & Xi, J. J. Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 23, 465–472 (2013).10.1038/cr.2013.45 ↗
4. Xiao, A., Wang, Z., Hu, Y., Wu, Y., Luo, Z., Yang, Z., Zu, Y., Li, W., Huang, P. & Tong, X. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res. 41, 141 (2013).10.1093/nar/gkt464 ↗
5. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P. & Lim, W. A. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).10.1016/j.cell.2013.02.022 ↗
6. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E. & Church, G. M. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).10.1126/science.1232033 ↗
7. Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X. & Makarova, K. S. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).10.1038/nature14299 ↗
8. Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M. & Jovanovic, M. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).10.1016/j.cell.2014.09.014 ↗
9. Nault, J. C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J. F., Balabaud, C., Calderaro, J., Laurent, A., Letexier, M., Bioulac-Sage, P., Calvo, F. & Zucman-Rossi, J. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 47, 1187–1193 (2015).10.1038/ng.3389 ↗
10. Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L. & Gu, Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing. Angew. Chem. Int. Ed. 54, 12029–12033 (2015).10.1002/anie.201506030 ↗
11. Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C. & Stöter, M. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).10.1038/nbt.2612 ↗
12. Slingerland, M., Guchelaar, H. J. & Gelderblom, H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today 17, 160–166 (2012).10.1016/j.drudis.2011.09.015 ↗
13. Zhang, L., Feng, Q., Wang, J., Sun, J., Shi, X. & Jiang, X. Microfluidic synthesis of rigid nanovesicles for hydrophilic reagents delivery. Angew. Chem. Int. Ed. 54, 3952–3956 (2015).10.1002/anie.201500096 ↗
14. Sun, J. S., Zhang, L., Wang, J. D., Feng, Q., Liu, D. B., Yin, Q. F., Xu, D. Y., Wei, Y. J., Ding, B. Q., Shi, X. H. & Jiang, X. Y. Tunable rigidity of (polymeric core)-(lipid shell) nanoparticles for regulated cellular uptake. Adv. Mater. 27, 1402–1407 (2015).10.1002/adma.201404788 ↗
15. Zhang, L., Feng, Q., Wang, J. L., Zhang, S., Ding, B. Q., Wei, Y. J., Dong, M. D., Ryu, J. Y., Yoon, T. Y., Shi, X. H., Sun, J. S. & Jiang, X. Y. Microfluidic synthesis of hybrid nanoparticles with controlled lipid layers: understanding flexibility-regulated cell-nanoparticle interaction. ACS Nano 9, 9912–9921 (2015).10.1021/acsnano.5b05792 ↗
16. Meng, H., Wang, M., Liu, H., Liu, X., Situ, A., Wu, B., Ji, Z., Chang, C. H. & Nel, A. E. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 9, 3540–3557 (2015).10.1021/acsnano.5b00510 ↗
17. Gao, W., Vecchio, D., Li, J., Zhu, J., Zhang, Q., Fu, V., Li, J., Thamphiwatana, S., Lu, D. & Zhang, L. Hydrogel containing nanoparticle-stabilized liposomes for topical antimicrobial delivery. ACS Nano 8, 2900–2907 (2014).10.1021/nn500110a ↗
18. Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z. Y. & Liu, D. R. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2014).10.1038/nbt.3081 ↗
19. Tseng, Y. C., Mozumdar, S. & Huang, L. Lipid-based systemic delivery of siRNA. Adv. Drug. Deliv. Rev. 61, 721–731 (2009).10.1016/j.addr.2009.03.003 ↗
20. Immordino, M. L., Dosio, F. & Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297–315 (2006).10.2217/17435889.1.3.297 ↗
21. Romberg, B., Hennink, W. E. & Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 55–71 (2008).10.1007/s11095-007-9348-7 ↗
22. Feng, Q., Yu, M. Z., Wang, J. C., Hou, W. J., Gao, L. Y., Ma, X. F., Pei, X. W., Niu, Y. J., Liu, X. Y. & Qiu, C. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials 35, 5028–5038 (2014).10.1016/j.biomaterials.2014.03.012 ↗
23. Spänkuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M. & Strebhardt, K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94, 1863–1877 (2002).10.1093/jnci/94.24.1863 ↗
24. Zhang, L., Zheng, W., Tang, R., Wang, N., Zhang, W. & Jiang, X. Gene regulation with carbon-based siRNA conjugates for cancer therapy. Biomaterials 104, 269–278 (2016).10.1016/j.biomaterials.2016.07.015 ↗
25. Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R. & Crowley, D. G. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380–384 (2014).10.1038/nature13589 ↗
26. Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T. & Anderson, D. G. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).10.1038/nbt.2884 ↗
27. Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E. & Doench, J. G. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).10.1126/science.1247005 ↗
28. Heintze, J., Luft, C. & Ketteler, R. A CRISPR CASe for high-throughput silencing. Front. Genet. 4, 193 (2013).10.3389/fgene.2013.00193 ↗